Last reviewed · How we verify
FOMIVIRSEN
Fomivirsen is a small molecule drug originally developed by Novartis and currently owned by the same company. It is classified as a fomivirsen and was FDA approved in 1998 for the treatment of cytomegaloviral retinitis. Fomivirsen is off-patent and has no active Orange Book patents, but there are no generic manufacturers available. It is used to treat a specific eye infection caused by the cytomegalovirus. As an off-patent drug with no generic alternatives, its commercial status is limited.
At a glance
| Generic name | FOMIVIRSEN |
|---|---|
| Sponsor | Novartis |
| Drug class | fomivirsen |
| Modality | Oligonucleotide |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
- Cytomegaloviral retinitis
Common side effects
Key clinical trials
- The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes (PHASE2)
- A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis (NA)
- A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) (PHASE2)
- A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOMIVIRSEN CI brief — competitive landscape report
- FOMIVIRSEN updates RSS · CI watch RSS
- Novartis portfolio CI